SGLT-2 inhibitors for diabetes may help prevent dementia, study finds

Researchers have called for randomised controlled trials into the role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in preventing dementia, after finding that people whose type 2 diabetes was treated with this group of drugs were less likely to develop Alzheimer’s disease or vascular dementia than those taking dipeptidyl peptidase-4 (DPP-4) inhibitors.

A previous study from Canada found a lower risk of dementia in people aged over 66 who took SGLT-2 inhibitors than in those taking DPP-4 inhibitors, but it did not look at the effects of these drugs on younger people or examine specific types of dementia, …